Roche Profit Hit By Genentech Deal But Ups Outlook

BASEL, Switzerland (Reuters) - Roche , the maker of the Tamiflu flu drug, missed forecasts with a 29 percent drop in first-half net profit, hit by costs related to its $47 billion acquisition of Genentech.

Topics:  basel   switzerland reuters     roche   tamiflu   genentech   profit hit   
BING NEWS:
  • UPS: Potential Opportunity In The Face Of Amazon Threat
    UPS has been losing market share to Amazon, but still has a solid competitive position and is exposed to ongoing growth in eCommerce. The overcapacity problem in the small parcel market is expected to ...
    06/3/2024 - 11:42 am | View Link
  • Smart Money Is Betting Big In UPS Options
    The general mood among these heavyweight investors is divided, with 28% leaning bullish and 50% bearish. Among these notable options, 7 are puts, totaling $408,639, and 7 are calls, amounting to ...
    05/29/2024 - 9:01 am | View Link
  • FDA sends warning letter to Roche researcher over Xofluza study issues
    The letter was dated Nov. 8. Roche's Genentech unit had been testing Xofluza for the reduction of direct transmission of influenza from otherwise healthy patients to household contacts.
    11/22/2023 - 8:31 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News